Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.

Biotech Recognizes the Year's Best

October 11, 2001

Biotech Recognizes the Year's Best
Outstanding products, companies, individuals, and business strategies are honored by peers

San Francisco, CA - October 11, 2001

Winners of the Best of Biotech 2001 and inductees into the Biotech Hall of Fame were announced Sunday night, October 7, at the 14th Annual Biotech Meeting at Laguna Niguel, a biotech CEO-only conference hosted by Burrill & Company and Kleiner Perkins Caufield & Byers.

Industry leaders also recognize deceased colleague Lisa J. Raines, who perished on September 11 in the crash of American Airlines Flight 77. Henri Termeer, Genzyme Chairman and Chief Executive Officer, offered words of remembrance and sadness. "Lisa was a great friend and a brilliant colleague," remarked Termeer. "She was a tremendous advocate for Genzyme and for the biotechnology industry. We will miss her." Ms. Raines had been with Genzyme since 1993 and was responsible for federal legislative and regulatory policy issues and provided strategic counsel on policy issues to all Genzyme product groups.

For a decade, the CEOs of the biotech industry have recognized the important achievements of the past year, heralding their colleagues and their individual contributors, as well as the companies behind the scientific breakthroughs and the business successes. The awards recognize industry leaders who have made significant contributions to biotech over the years as well as those who continue to make biotech one of the most exciting, unpredictable and life-affirming industries in the world.

Nominations are made by the Biotech Meeting Advisory Committee and sent to the industry CEOs, who then vote in each of the seven categories. "There is no greater recognition than that of one’s peers," commented G. Steven Burrill, CEO of Burrill & Company, a San Francisco-based life sciences merchant bank.

This year’s winners are:

The Best of Biotech 2001
Best New Approved "Therapeutic" Product:
Gleevec™ (imatinib mesylate), Novartis’ oncology drug for the treatment of chronic myeloid leukemia (CML), demonstrated significant patient benefits in early testing and was granted accelerated approval by the FDA. The advantage of Gleevec is that it kills CML cells but leaves normal cells alone. Preliminary results, announced in December of 2000, revealed that 100 percent of patients treated with Gleevec, aka STI-571, had their blood counts return to normal. By defining what drives the growth of cancer cells, Novartis hopes it will be able to target cancer cells with more effective and less toxic therapies.

Best New Approved Product Other Than a Therapeutic: Biosite’s Triage® BNP (B-type natriuretic peptide) Test to diagnose congestive heart failure (CHF) afforded 98% accuracy in initial studies. There are 5 million people diagnosed with CHF in the United States and approximately 550,000 new cases are identified each year. The Triage BNP test is the first blood test approved by the FDA as an aid in the diagnosis of congestive heart failure.

Most Important Financing of the Year: Human Genome Sciences for successfully raising $948.8 million in follow-on financing during 4Q 2000. With drug candidates Repifermin (for wound care, mucositis, and ulcerative colitis), Mirostipen™ (for cancer treatment side effects), BLyS (for immunodeficiency), and Albuferon™ (for Hepatitis C) in or approaching human trials, the company is on track to have at least one drug approved by the FDA within nine years.

Most Creative and Significant Strategic Alliance Deal: CuraGen/Bayer– a comprehensive alliance to discover, develop, and jointly commercialize small molecule drugs to treat obesity and adult onset diabetes as well as a broad collaborative effort to apply CuraGen’s functional genomic technologies and pharmacogenomics expertise to evaluate Bayer’s developmental and preclinical pipeline of pharmaceutical compounds…a deal valued at $1.4 billion. The worldwide annual market for obesity and diabetes therapies is estimated to be $98 billion.

The Biotech Meeting also recognizes the contributions made by organizations and individuals:

2001 Company Inductee into the Biotech Hall of Fame: IDEC Pharmaceuticals.
Founded in 1986, IDEC Pharmaceuticals applies monoclonal antibody technology in the development of cancer products, autoimmune and inflammatory diseases, rheumatoid arthritis, immune thrombocytopenic purpura (ITP), and allergic asthma. The company’s portfolio of marketed products includes Rituxan®, the first approved monoclonal antibody to treat cancer. Rituxan is used to treat low-grade, follicular, relapsed or refractory CD-20 positive B-cell non-Hodgkin’s lymphomas (NHL). Today it is the most frequently used treatment for NHL in the U.S. IDEC also is seeking marketing approval for its second product, Zevalin™, an experimental drug that targets radiation to tumors. On September 11, 2001, an FDA advisory panel backed the immediate approval of Zevalin, which, if approved, would be the first treatment to use radioimmunotherapy to kill tumors. The agency, which usually follows the advice of its panels, is expected to arrive at a final decision by January 8, 2002.

IDEC Pharmaceutical’s management team is led by William H. Rastetter, Ph.D., who has served as its President and Chief Executive Officer since 1986.

2001 Scientific Contribution Inductee to the Biotech Hall of Fame: Dr. James Thomson
Dr. James Thomson, who with a team of scientists at the University of Wisconsin-Madison successfully isolated and cultured human embryonic stem cells in 1998, is an internationally renowned developmental biologist. Because embryonic stem cells are the precursor cells to all other cell types in the human body, Dr. Thomson’s accomplishments have set the stage for a revolution in medicine and science. Indeed, the discoveries made within Dr. Thomson’s laboratory hold great promise for those suffering from cell-based diseases such as juvenile diabetes, Parkinson’s and heart disease.

2001 Individual Inductee into the Biotech Hall of Fame: Carl B. Feldbaum, Esq.
Under the guidance of Carl Feldbaum, the Biotechnology Industry Organization (BIO) has become the world’s largest organization to serve and represent the biotechnology industry. His leadership has engendered strong ongoing relationships with the White House, Congress, and federal regulatory agencies including the FDA, EPA, NIH, and USDA. Mr. Feldbaum’s considerable government and corporate experience has come into play on many occasions as he has communicated the sentiments of the more than 1,000 biotechnology companies, academic institutions, and state biology centers in the U.S. and abroad that comprise BIO’s membership.

Prior to his appointment as President of BIO, Mr. Feldbaum was Chief of Staff for Senator Arlen Specter (R-PA). He also has served as President of Palomar Corporation, Assistant to the U.S. Secretary of Energy, and Inspector General for defense intelligence in the U.S. Department of Defense. Mr. Feldbaum co-authored Looking the Tiger in the Eye: Confronting the Nuclear Threat, which was awarded the Christopher Medal and was designated a New York Times Notable Book of the Year for 1988. He received his B.A. in Biology from Princeton University and his J.D. from the University of Pennsylvania.

Past winners of the Best of Biotech awards


2001 Winner is IDEC Pharmaceuticals

1997 Winners 1998 Winner 1999 Winner 2000 Winner
Amgen Centocor Immunex Corp. Millennium Pharmaceuticals

2001 Winner for Scientific Achievement is James Thomson, University of Wisconsin

1997 Winners 1998 Winner 1999 Winner 2000 Winner
Dr. Stanley Cohen Amgen Roslin Institute Celera
Herb Boyer      
Leroy Hood      
Dr. Caesar Millstein      
Cetus Corporation      

2001 Winner for Special Recognition for an Individual is Carl Feldbaum, President of BIO

1997 Winners 1998 Winner 1999 Winner 2000 Winner
Fred Frank Bill Rutter Herbert Schoemaker Gordon Binder
George Rathmann     G. Steven Burrill
Bob Swanson     Brook Byers
Henri Termeer      
Alex Zaffaroni      

Burrill & Company

Burrill & Company is a San Francisco-based life sciences merchant bank. Burrill & Company’s core business is venture capital investing across the entire spectrum of life sciences including human healthcare biotechnology, agricultural biotechnology, nutraceuticals, human healthcare diagnostics, biomaterials and bioprocesses. Supportive activities include strategic partnering for life science companies, sponsorship of industry conferences and publication of industry reports, and maintenance of an online marketplace for biopharmaceutical deal making.

If you would like additional information about Burrill & Company, please feel free to contact us:

Burrill & Company
One Embarcadero Center,
Suite 2700
San Francisco, CA 94111
Main Phone: 415-591-5400
Fax: 415-591-5401

Back to News list  
News Archive: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All